Safety Tolerability and Pharmacokinetic of BI 411034
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 411034 (PIB) in Healthy Male Volunteers (Randomised, Single-blind, Placebocontrolled Within Dose Groups, Phase I Study)
The primary objective of the current study is to investigate the safety, tolerability and pharmacokinetics of BI 411034 in healthy male volunteers following oral administration of single rising doses.
The secondary objective is to explore dose proportionality of BI 411034 in CYP2C19 (Cytochrome P450) genotyped extensive metabolisers (EM).
Another objective is to compare the safety and pharmacokinetic profiles between two different groups of CYP2C19 genotyped subjects, extensive metabolisers (EM) and poor metabolisers (PM)
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
-
Ingelheim、ドイツ
- 1308.1.1 Boehringer Ingelheim Investigational Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
1. Healthy male subjects
Exclusion criteria:
1. Any relevant deviation from healthy conditions
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
---|---|
プラセボコンパレーター:プラセボ
経口投与用溶液
|
経口投与用溶液
|
実験的:BI 411034 low dose - group 1
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 low dose - group 2
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 medium dose - group 3
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 medium dose - group 4
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 medium dose - group 5
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 high dose - group 6
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 high dose - group 7
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
実験的:BI 411034 high dose - group 8
Solution for oral administration
|
Low dose solution for oral administration
Medium dose solution for oral administration
High dose solution for oral administration
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Number of Participants With Drug Related AEs
時間枠:From drug administration until end of trial examination, up to 13 days
|
Number of participants with drug related adverse events (AEs)
|
From drug administration until end of trial examination, up to 13 days
|
Clinically Relevant Abnormalities for Physical Examinations, Vital Signs, ECG, Laboratory Tests
時間枠:From drug administration until end of trial examination, up to 13 days
|
Clinically relevant abnormalities for physical examinations, vital signs (blood pressure, pulse rate, oral body temperature, orthostasis test), 12-lead electrocardiogram (ECG) and clinical laboratory tests.
Clinically relevant abnormalities are reported by the investigator as adverse events (AEs).
|
From drug administration until end of trial examination, up to 13 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Maximum Measured Concentration (Cmax )
時間枠:2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Maximum measured concentration of the analyte (BI 411034) in plasma
|
2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Time to Maximum Measured Concentration (Tmax)
時間枠:2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Time from dosing to maximum measured concentration
|
2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Area Under the Curve From 0 Extrapolated to Infinity (AUC0-infinity)
時間枠:2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Area under the concentration-time curve of the analyte (BI 411034) in plasma over the time interval from 0 extrapolated to infinity
|
2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Amount of Analyte Eliminated in Urine From 0h to 4h (Ae0-4)
時間枠:2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
Amount of analyte (BI 411034) eliminated in urine from the time point 0h to time point 4h.
|
2 hours (h) before drug administration and 10 minutes (min), 20min, 30min, 45min, 1h 15min, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 48h, and 72h after drug administration
|
協力者と研究者
スポンサー
出版物と役立つリンク
便利なリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 1308.1
- 2011-004840-23 (EudraCT番号:EudraCT)
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。
プラセボの臨床試験
-
Palacky University完了
-
Universidade Federal do ParaConselho Nacional de Desenvolvimento Científico e Tecnológico完了
-
Advice Pharma Group srl積極的、募集していない肥満 | 栄養障害 | 体重 | 減量 | 食生活 | 太りすぎと肥満 | 健康行動 | ダイエット、健康 | ダイエット習慣 | ライフスタイル | 栄養、健康 | 行動障害イタリア
-
University Hospital, Strasbourg, France積極的、募集していない